Which drug is listed as the better choice for obesity treatment?

Which drug is listed as the better choice for obesity treatment?

• A. Orlistat
• B. Lorcaserin (serotonin receptor agonist)
• C. Topiramate
• D. Phentermine/topiramate (Qsymia)

Answer: (B)

The idea behind choosing an obesity drug is to weigh how well it helps with weight loss against how well patients tolerate it and what safety risks it carries. Lorcaserin works by selectively activating serotonin-2C receptors in the hypothalamus, which dampens appetite and leads to lower caloric intake. This tends to produce modest but meaningful long-term weight loss with a generally favorable tolerability profile, especially compared with stimulant-like drugs. Orlistat lowers weight by inhibiting fat absorption, but the downside is mainly gastrointestinal issues that can limit adherence and yield only modest weight loss. Topiramate, either alone or combined with phentermine, can produce more substantial weight loss but brings cognitive effects and other tolerability concerns, and the combination carries additional risks such as teratogenicity and cardiovascular considerations. Given these trade-offs, lorcaserin is often viewed as the better-balanced option for many patients seeking pharmacologic treatment for obesity, offering consistent appetite suppression with a tolerable safety profile.

The idea behind choosing an obesity drug is to weigh how well it helps with weight loss against how well patients tolerate it and what safety risks it carries. Lorcaserin works by selectively activating serotonin-2C receptors in the hypothalamus, which dampens appetite and leads to lower caloric intake. This tends to produce modest but meaningful long-term weight loss with a generally favorable tolerability profile, especially compared with stimulant-like drugs. Orlistat lowers weight by inhibiting fat absorption, but the downside is mainly gastrointestinal issues that can limit adherence and yield only modest weight loss. Topiramate, either alone or combined with phentermine, can produce more substantial weight loss but brings cognitive effects and other tolerability concerns, and the combination carries additional risks such as teratogenicity and cardiovascular considerations. Given these trade-offs, lorcaserin is often viewed as the better-balanced option for many patients seeking pharmacologic treatment for obesity, offering consistent appetite suppression with a tolerable safety profile.